SSP
PCVX icon

Sixth Street Partners’s Vaxcyte PCVX Stock Holding History

Sixth Street Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.1M Buy
+1,464,812
New +$79.6M 0.01% 883

Other funds holding PCVX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Sixth Street Partners's PCVX Position: Q2 2026 in Review

Sixth Street Partners opened a new position in Vaxcyte (PCVX) in Q2 2026: 1,464,812 shares worth $85.1M. The stake represents 0.01% of the portfolio and ranks #883 among its holdings.

266 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Sixth Street Partners held 1,464,812 shares of Vaxcyte worth $85.1M as of Q2 2026.
  • Vaxcyte was a new Sixth Street Partners position in Q2 2026.
  • Vaxcyte made up 0.01% of Sixth Street Partners's portfolio in Q2 2026, its #883 holding.
  • 266 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Sixth Street Partners's 13F filing for Q2 2026, filed 14 Aug 2026.